| Name | Title | Contact Details |
|---|
LegalBillReview.com helps in-house legal teams save time, reduce legal expenses, and improve attorney relationships. Our team of experienced attorneys identify excessive charges and billing errors, then cooperatively work with outside counsel to correct the bill. Call or email us today! (484) 430-4000 Requests@legalbillreview.com
ABOUT KSB KSB is one of the worlds leading suppliers of pumps, valves and related systems. KSB combines innovative technology and excellent service to provide intelligent solutions. This approach means that KSB employees are close to customers on all continents, providing them with pumps, valves and systems for almost all applications involving the transportation of liquids. A comprehensive range of services rounds off this customer-focused portfolio. KSB has been growing continuously since it was founded in 1871. Today the Group has a presence on all continents with its own sales and marketing companies, manufacturing facilities and service operations. More than 15,600 employees generate annual consolidated sales revenue of two billion euros. KSB WORLDWIDE With production plants, sales offices and agents in more than 100 countries, KSB is close to its customers throughout the world. Direct contact with local KSB specialists makes it easier for companies to implement their projects quickly, flexibly and at a high level of quality. KSB IN THE MEDIA www.facebook.com/KSB.Company www.twitter.com/KSBcompany www.youtube.com/user/ksbcompany https://www.instagram.com/ksbcompany/ FROM A SINGLE SOURCE: PUMPS AND VALVES, SERVICES AND SYSTEMS: • Pumps and valves for industrial applications • Comprehensive KSB services and original spare parts • Pumps, valves and systems for building services • Automation and drive solutions • Pumps, valves and systems for renewable energy applications • Slurry pumps for mining, suction dredgers and the oil sand industry • Pumps, valves and systems for water applications • Pumps, valves and systems for waste water applications • Pumps, valves and systems for energy applications
The National Basketball Association (NBA) is a professional sports league in North America, established in 1946. Headquartered in New York City, the NBA is one of the four major professional sports leagues in the United States and Canada. It is known for its competitive basketball games, iconic players, and extensive global reach. The NBA organizes regular season games, playoffs, and the NBA Finals, attracting millions of viewers worldwide. It also oversees the NBA G League, which serves as a developmental platform for players and staff, and runs Jr. NBA programs to promote basketball among youth. The league is committed to community outreach through NBA Cares, focusing on building facilities and supporting education and health initiatives. With a strong presence in over 200 countries, the NBA utilizes advanced technology and media platforms to engage fans and enhance their experience.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.